Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Future of the particle replication in nonwetting templates (PRINT) technology.

Xu J, Wong DH, Byrne JD, Chen K, Bowerman C, DeSimone JM.

Angew Chem Int Ed Engl. 2013 Jun 24;52(26):6580-9. doi: 10.1002/anie.201209145. Epub 2013 May 13. Review.

2.

The pursuit of a scalable nanofabrication platform for use in material and life science applications.

Gratton SE, Williams SS, Napier ME, Pohlhaus PD, Zhou Z, Wiles KB, Maynor BW, Shen C, Olafsen T, Samulski ET, Desimone JM.

Acc Chem Res. 2008 Dec;41(12):1685-95. doi: 10.1021/ar8000348.

3.

PRINT: a novel platform toward shape and size specific nanoparticle theranostics.

Perry JL, Herlihy KP, Napier ME, Desimone JM.

Acc Chem Res. 2011 Oct 18;44(10):990-8. doi: 10.1021/ar2000315. Epub 2011 Aug 2. Review.

4.

Direct fabrication and harvesting of monodisperse, shape-specific nanobiomaterials.

Rolland JP, Maynor BW, Euliss LE, Exner AE, Denison GM, DeSimone JM.

J Am Chem Soc. 2005 Jul 20;127(28):10096-100.

PMID:
16011375
5.

Challenging nature's monopoly on the creation of well-defined nanoparticles.

Jeong W, Napier ME, DeSimone JM.

Nanomedicine (Lond). 2010 Jun;5(4):633-9. doi: 10.2217/nnm.10.34.

PMID:
20528457
6.

Shape-specific, monodisperse nano-molding of protein particles.

Kelly JY, DeSimone JM.

J Am Chem Soc. 2008 Apr 23;130(16):5438-9. doi: 10.1021/ja8014428. Epub 2008 Apr 1.

PMID:
18376832
7.

Engineering nanomedicines using stimuli-responsive biomaterials.

Wang Y, Byrne JD, Napier ME, DeSimone JM.

Adv Drug Deliv Rev. 2012 Aug;64(11):1021-30. doi: 10.1016/j.addr.2012.01.003. Epub 2012 Jan 14.

8.

Nanofabricated particles for engineered drug therapies: a preliminary biodistribution study of PRINT nanoparticles.

Gratton SE, Pohlhaus PD, Lee J, Guo J, Cho MJ, Desimone JM.

J Control Release. 2007 Aug 16;121(1-2):10-8. Epub 2007 Jun 2.

9.

Scalable, shape-specific, top-down fabrication methods for the synthesis of engineered colloidal particles.

Merkel TJ, Herlihy KP, Nunes J, Orgel RM, Rolland JP, DeSimone JM.

Langmuir. 2010 Aug 17;26(16):13086-96. doi: 10.1021/la903890h.

10.

More effective nanomedicines through particle design.

Wang J, Byrne JD, Napier ME, DeSimone JM.

Small. 2011 Jul 18;7(14):1919-31. doi: 10.1002/smll.201100442. Epub 2011 Jun 22. Review.

11.

Microfabricated engineered particle systems for respiratory drug delivery and other pharmaceutical applications.

Garcia A, Mack P, Williams S, Fromen C, Shen T, Tully J, Pillai J, Kuehl P, Napier M, Desimone JM, Maynor BW.

J Drug Deliv. 2012;2012:941243. doi: 10.1155/2012/941243. Epub 2012 Feb 9.

12.

Effect of aspect ratio and deformability on nanoparticle extravasation through nanopores.

Kersey FR, Merkel TJ, Perry JL, Napier ME, DeSimone JM.

Langmuir. 2012 Jun 12;28(23):8773-81. doi: 10.1021/la301279v. Epub 2012 May 29.

13.

Top-down particle fabrication: control of size and shape for diagnostic imaging and drug delivery.

Canelas DA, Herlihy KP, DeSimone JM.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009 Jul-Aug;1(4):391-404. doi: 10.1002/wnan.40. Review.

14.

Nanoparticles for drug delivery: the need for precision in reporting particle size parameters.

Gaumet M, Vargas A, Gurny R, Delie F.

Eur J Pharm Biopharm. 2008 May;69(1):1-9. Epub 2007 Aug 7. Review.

PMID:
17826969
15.

Nanoparticles in the pharmaceutical industry and the use of supercritical fluid technologies for nanoparticle production.

Sheth P, Sandhu H, Singhal D, Malick W, Shah N, Kislalioglu MS.

Curr Drug Deliv. 2012 May;9(3):269-84. Review.

PMID:
22283656
16.

Pushing nanocrystal synthesis toward nanomanufacturing.

Skrabalak SE, Xia Y.

ACS Nano. 2009 Jan 27;3(1):10-5. doi: 10.1021/nn800875p. Review.

PMID:
19206242
17.

Nanotoxicological classification system (NCS) - a guide for the risk-benefit assessment of nanoparticulate drug delivery systems.

Keck CM, Müller RH.

Eur J Pharm Biopharm. 2013 Aug;84(3):445-8. doi: 10.1016/j.ejpb.2013.01.001. Epub 2013 Jan 16. Review.

PMID:
23333302
18.

Tailor-made nanoparticles via gas-phase synthesis.

Gutsch A, Mühlenweg H, Krämer M.

Small. 2005 Jan;1(1):30-46. Review.

PMID:
17193347
19.

Engineered PRINT(®) nanoparticles for controlled delivery of antigens and immunostimulants.

Beletskii A, Galloway A, Rele S, Stone M, Malinoski F.

Hum Vaccin Immunother. 2014;10(7):1908-13. doi: 10.4161/hv.28817.

20.

Reductively responsive siRNA-conjugated hydrogel nanoparticles for gene silencing.

Dunn SS, Tian S, Blake S, Wang J, Galloway AL, Murphy A, Pohlhaus PD, Rolland JP, Napier ME, DeSimone JM.

J Am Chem Soc. 2012 May 2;134(17):7423-30. doi: 10.1021/ja300174v. Epub 2012 Apr 19.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk